文献速递糖尿病肥胖与代谢综合征

脂联素通过APPL1-SIRT1-PGC-1α调控MOTS-c改善小鼠胰岛素抵抗

Adiponectin treatment improves insulin resistance in mice by regulating the expression of the mitochondrial-derived peptide MOTS-c and its response to exercise via APPL1-SIRT1-PGC-1α.
PubMed 文献 · Diabetologia · 2020-09-03

研究在高脂饮食小鼠、脂联素敲除小鼠及C2C12肌管中探讨脂联素对线粒体衍生肽MOTS-c的调控。发现脂联素经APPL1-SIRT1-PGC-1α通路促进骨骼肌MOTS-c表达与分泌,运动及外源脂联素或MOTS-c可提升MOTS-c水平并改善胰岛素抵抗。

要点

  • 脂联素通过APPL1-SIRT1-PGC-1α通路调控骨骼肌MOTS-c的产生和/或分泌。
  • 高脂饮食下调血浆和骨骼肌MOTS-c水平,运动或脂联素注射可逆转。
  • MOTS-c是糖尿病治疗的潜在新靶点。

核心结论

  • 脂联素信号通过APPL1-SIRT1-PGC-1α通路调控骨骼肌MOTS-c的产生和/或分泌。
  • MOTS-c是治疗糖尿病的潜在新治疗靶点。

研究设计与样本

  • 使用高脂饮食、运动方案及腹腔注射重组小鼠脂联素(Acrp30)或MOTS-c的野生型C57BL/6小鼠。
  • 使用腹腔注射Acrp30的脂联素敲除(Adipoq-/-)小鼠(C57BL/6背景)。
  • C2C12肌管分别用SIRT1抑制剂、PGC-1α抑制剂、SIRT1激活剂、表达活性APPL1的质粒、pcDNA-SIRT1或针对APPL1、SIRT1、PGC-1α的siRNA处理。

主要发现

  • Adipoq-/-小鼠血浆和骨骼肌MOTS-c水平下调。
  • C2C12肌管中脂联素增加MOTS-c的mRNA表达。
  • 脂联素处理后APPL1蛋白水平与C2C12肌管中MOTS-c蛋白和mRNA水平正相关。
  • SIRT1过表达增加脂联素诱导的MOTS-c、SIRT1和PGC-1α的mRNA和蛋白表达。
  • 药理学和遗传学抑制PGC-1α可抑制SIRT1过表达诱导的MOTS-c mRNA和蛋白水平升高。

临床怎么用

  • MOTS-c可作为糖尿病治疗的潜在新型靶点。
  • 运动可能通过脂联素-APPL1-SIRT1-PGC-1α通路提升MOTS-c水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Adiponectin stimulates mitochondrial biogenesis through peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), a major regulator of mitochondrial biogenesis. MOTS-c (mitochondrial open reading frame of the 12S rRNA) is a biologically active mitochondrial-derived peptide encoded by mitochondrial DNA. It influences the mechanisms of obesity and diabetes. We hypothesised that the adiponectin pathway may regulate the production and/or secretion of MOTS-c in skeletal muscle. We aimed to determine whether exercise and adiponectin affect MOTS-c to improve insulin resistance in mice. METHODS: To investigate this hypothesis, we used wild-type C57BL/6 mice subjected to high-fat diet, an exercise regimen, and i.p. injection of recombinant mouse adiponectin (Acrp30) or MOTS-c, and adiponectin knockout (Adipoq-/-) mice (C57BL/6 background) subjected to i.p. injection of Acrp30. C2C12 myotubes were also treated with sirtuin 1 (SIRT1) inhibitor, PGC-1α inhibitor, SIRT1 activator, plasmid-expressed active APPL1 (adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper), pcDNA-SIRT1, or siRNA against APPL1, SIRT1 or PGC-1α. RESULTS: In Adipoq-/- mice, MOTS-c levels in the plasma and skeletal muscle were downregulated. In C2C12 myotubes, adiponectin increased the mRNA expression of MOTS-c. APPL1 protein level following adiponectin treatment positively correlated with MOTS-c protein and mRNA levels in C2C12 myotubes. SIRT1 overexpression increased the adiponectin-induced mRNA and protein expression of MOTS-c, SIRT1 and PGC-1α. Pharmacologic and genetic inhibition of PGC-1α suppressed the increases in MOTS-c mRNA and protein levels induced by SIRT1 overexpression. In mice, plasma and skeletal muscle MOTS-c levels were significantly downregulated following high-fat-diet. Exercise and i.p. Acrp30 or MOTS-c increased MOTS-c levels and adiponectin mRNA and protein expression in the plasma and skeletal muscle. CONCLUSIONS/INTERPRETATION: Our findings showed that the APPL1-SIRT1-PGC-1α pathway regulates the production and/or secretion of skeletal muscle MOTS-c by mediating adiponectin signalling. Our study provides an insight into the cellular and molecular pathways underlying the pathogenesis of diabetes and shows that MOTS-c is a potential novel therapeutic target in the treatment of diabetes. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Guo Q, Chang B, Yu QL, et al. Adiponectin treatment improves insulin resistance in mice by regulating the expression of the mitochondrial-derived peptide MOTS-c and its response to exercise via APPL1-SIRT1-PGC-1α. Diabetologia. 2020. PMID: 32880686. doi:10.1007/s00125-020-05269-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。